gematik explains ePA data protection and security architecture, confirming that only patients and authorised medical personnel can access records through Germany's secure health network.
gematik (German Digital Health) · GermanyNew TI-Messenger specification enables integration into primary healthcare software systems, allowing secure messaging directly within existing practice and pharmacy applications.
gematik (German Digital Health) · GermanyGuidance on integration of hospital patient portals with the electronic health record (ePA) and primary systems in downstream care settings, with process and care pathway recommendations.
gematik (German Digital Health) · Germanygematik publishes guidance on implementing and using KIM (secure healthcare email) in care facilities, based on pilot experience in Hamburg region.
gematik (German Digital Health) · GermanyWorking group recommends criteria and priorities for digitising paper-based healthcare and care processes under the 'Gemeinsam Digital' strategy.
gematik (German Digital Health) · GermanyG-BA establishes a new U10 preventive health screening examination for children and integrates J1 adolescent screening documentation into the Yellow Booklet.
G-BA (Federal Joint Committee) · GermanyOrgan donation declarations submitted via GesundheitsID have reached 300,000 total, with 75% of new declarations now submitted digitally through the ePA app.
gematik (German Digital Health) · Germanygematik's Cyber Defense Center head describes vulnerability detection, threat analysis and protective measures for the German health IT infrastructure.
gematik (German Digital Health) · GermanyIQWiG General Methods 8.0 entered force in December 2025, introducing new methods for hospital minimum volume standards and HTA assessment.
IQWiG (German HTA) · GermanyePA apps are receiving updates enabling push notifications for patient activity, allowing users to control alerts about record access and document uploads.
gematik (German Digital Health) · GermanyShareholders mandate gematik to create a roadmap for consolidating and unifying the operation of core Telematic Infrastructure components.
gematik (German Digital Health) · GermanyG-BA adds left heart catheterisation to the physician second-opinion programme and expands access pathways for patients.
G-BA (Federal Joint Committee) · GermanyG-BA found insufficient evidence to extend organised colorectal cancer screening to younger individuals with familial risk.
G-BA (Federal Joint Committee) · GermanyAnnual survey of 5,000 healthcare facilities and 1,400 insured persons shows electronic patient record adoption at 70% in practices and 50% in hospitals, with TI-Gateway improving stability.
gematik (German Digital Health) · GermanyOver 300 representatives from manufacturers, providers and partner organisations met at the TI-Forum 2026 to discuss operation, security and future development of Germany's Telematic Infrastructure.
gematik (German Digital Health) · GermanyIQWiG finds insufficient evidence to change colorectal cancer screening age thresholds or colonoscopy intervals; recommends screening from age 50.
IQWiG (German HTA) · GermanyIQWiG guidance on the importance of patient-reported outcomes in clinical trials and benefit assessments, illustrated by asciminib for chronic myeloid leukaemia.
IQWiG (German HTA) · GermanyIQWiG and LSE researchers discuss the first Joint Clinical Assessment under the EU HTA Regulation and its implications for evidence generation.
IQWiG (German HTA) · GermanyIQWiG assessed manual acupuncture for migraine prophylaxis in adults, finding limited benefit compared with prevention medication and identifying evidence gaps.
IQWiG (German HTA) · Germanygematik announces final deadline for healthcare professionals to exchange digital credentials (Heilberufsausweise).
gematik (German Digital Health) · GermanyThe Innovation Committee of the Federal Joint Committee received a record number of applications for project funding to develop and advance medical guidelines.
G-BA (Federal Joint Committee) · GermanyRegister now for the IQWiG Autumn Symposium on 20 November 2026 in Cologne! Cost pressures within the health care system are mounting, making the issue of low-value care all the more pressing: but how can medical serv...
IQWiG (German HTA) · GermanyPressemitteilung des Innovationsausschusses beim Gemeinsamen Bundesausschuss vom 21. August 2026.
G-BA (Federal Joint Committee) · GermanyNew information and updates on our website. New information in the topic medicinal products New information in the topic licensing New information in the topic clinical trials New information in the topic Pharmacovigi...
BfArM (Federal Institute for Drugs) · GermanyThe G-BA Innovation Committee announces that an Innovation Fund project has further developed an S3 guideline on conduct disorders in children and adolescents.
G-BA (Federal Joint Committee) · GermanyUntil 2024, the “BfArM4Health” blog provided insights intoBfArM’s work and key developments in healthcare. Experts introduced their areas of responsibility and presented selected projects.
BfArM (Federal Institute for Drugs) · GermanyHere you will find all statistics listed in the topic Licensing. Processing Statistics Marketable Medicinal Products in the Responsibility of theBfArM Statistics "Complementary and Alternative Medicines and Traditiona...
BfArM (Federal Institute for Drugs) · GermanyWe move forward - since 1994! In 2024 the Federal Institute for Drugs and Medical Devices (BfArM) celebrated its 30th anniversary. Since 1994, the agency is working to ensure the efficacy and safety of medicinal produ...
BfArM (Federal Institute for Drugs) · GermanyThe publications of the Federal Institute for Drugs and Medical Devices offer a further source of information. Annual reports of the Federal Institute for Drugs and Medical Devices
BfArM (Federal Institute for Drugs) · GermanyPressemitteilung des Innovationsausschusses beim Gemeinsamen Bundesausschuss vom 17. Juli 2026.
G-BA (Federal Joint Committee) · GermanyIQWiG publishes Cancer Medicines Forum workshop results proposing a roadmap for systematic implementation of cancer treatment optimization studies.
IQWiG (German HTA) · GermanyPressemitteilung des Innovationsausschusses beim Gemeinsamen Bundesausschuss vom 10. Juli 2026.
G-BA (Federal Joint Committee) · GermanyIQWiG received six commissions from the Federal Ministry of Health to develop scientific recommendations for minimum volume standards in hospital care under the German Hospital Reform Act 2024.
IQWiG (German HTA) · GermanyIQWiG notes linvoseltamab received conditional marketing authorisation in April 2025 but comparative evidence is lacking until 2026.
IQWiG (German HTA) · GermanyBiotest Pharma recalls batch C795316P01 of Yimmugo (human normal immunoglobulin) 100mg/ml, 100ml vials, expiry 31.08.2028.
Paul-Ehrlich-Institut · GermanyRegeneron recalls one batch of Libtayo (Cemiplimab) 350 mg due to a sealing defect in the vial.
Paul-Ehrlich-Institut · GermanyIQWiG finds insufficient long-term follow-up data in cemiplimab trials for cutaneous squamous cell carcinoma, echoing prior EMA concerns.
IQWiG (German HTA) · GermanyIQWiG's benefit assessment of lecanemab for early-stage Alzheimer's disease, based on previously unpublished manufacturer data, finds no proven added benefit over current standard care.
IQWiG (German HTA) · GermanyIQWiG completed the first joint clinical assessment under the new EU HTA process for tovorafenib in paediatric low-grade glioma, approved by the Member State Coordination Group.
IQWiG (German HTA) · GermanyIQWiG determines considerable added benefit of trastuzumab deruxtecan for HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma based on DESTINY-Gastric04 trial.
IQWiG (German HTA) · Germany